Accessibility Menu
Cumberland Pharmaceuticals logo

Cumberland Pharmaceuticals(NASDAQ) CPIX

Market Cap$116.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-40%
5 Year+248%
1 Year+207%
1 Month+61%
$7.78
+1.30%
+0.10Today
After hours$7.71-$0.07 (-0.96%)
Cumberland Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 7.802026-08-07
Cumberland Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+50.58%USD 5.182026-07-31
1 month+60.94%USD 4.852026-07-08
3 month+114.93%USD 3.632026-05-08
Year to date+152.73%USD 3.092025-12-31
1 year+206.67%USD 2.542025-08-07
3 year+603.4%USD 1.112023-08-08
5 year+248.05%USD 2.242021-08-06
Since inception-40.23%USD 13.052009-08-11

Cumberland Pharmaceuticals Financials at a Glance

Market Cap

$116.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$31.27M

Net Income (TTM)

-$10.61M

EPS (TTM)

-$0.72

P/E Ratio

-10.85

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Price

$7.78

Volume

33,858

Open

$7.73

Previous Close

$7.80

Daily Range

$7.55 - $7.99

52-Week Range

$1.43 - $8.23

Estimated Earnings Date

Nov 3, 2026

CPIX News

Foolcom-Featured.png

Cumberland (CPIX) Q2 Revenue Up 10%

Motley Fool Markets TeamAug 6, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee, focused on acquiring, developing, and commercializing innovative branded prescription products. The company addresses unmet medical needs in hospital acute care, gastroenterology, and oncology. It operates mainly in the U.S. but has a growing network of international partners.

Products and Services

Acetadote: Treats acetaminophen poisoning.

Caldolor: Intravenous ibuprofen for treating pain and fever.

Kristalose: Oral solution for constipation.

Omeclamox-Pak: Treats H. pylori infections and related ulcers.

Sancuso: Prevents nausea and vomiting in chemotherapy patients.

Vaprisol: Treats hyponatremia in hospital settings.

Vibativ: Treats serious bacterial infections.

What Makes Cumberland Pharmaceuticals Inc. Special

Cumberland Pharmaceuticals Inc. differentiates itself through its focus on niche markets with specialized products addressing poorly met medical needs. This strategy reduces competition intensity and enhances the company’s ability to penetrate specific markets effectively.

Five Things You Need to Know

The company's primary markets include hospital acute care, gastroenterology, and oncology.

Cumberland’s leadership team has deep industry experience with a proactive approach to regulatory landscapes.

The company actively pursues strategic acquisitions to expand its product portfolio.

Cumberland is focused on international expansion to diversify revenue and mitigate domestic risks.

The company is committed to sustainable practices, as evidenced by its 2019 Sustainability Report.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

93

CEO

A. J. Kazimi, MBA

Website

www.cumberlandpharma.com

Headquarters

Nashville, TN 37203, US

CPIX Financials

Key Financial Metrics (TTM)

Gross Margin

83.37%

Operating Margin

-30.79%

Net Income Margin

-33.92%

Return on Equity

-47.10%

Return on Capital

-7.96%

Return on Assets

-16.87%

Earnings Yield

-9.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$116.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.98M

Volume

33.86K

Avg. Volume

111.94K

Financials (TTM)

Gross Profit

$26.07M

Operating Income

-$9.63M

EBITDA

-$5.65M

Operating Cash Flow

$1.14M

Capital Expenditure

-$114.37K

Free Cash Flow

$1.02M

Cash & ST Invst.

$3.86M

Total Debt

$4.71M

Cumberland Pharmaceuticals Performance Analysis

Cumberland Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 42,010,94916.7%
20232023-12-31USD 39,552,507-5.9%
20242024-12-31USD 37,867,945-4.3%
20252025-12-31USD 44,521,43117.6%
Cumberland Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-23.5%
Q42025-12-3165.0%
Q12026-03-31-33.2%
Q22026-06-30-98.2%
Cumberland Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.3862.6%
20232023-12-31USD -0.4414.8%
20242024-12-31USD -0.464.9%
20252025-12-31USD -0.19-58.6%
Cumberland Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-160.0%
Q42025-12-3127.4%
Q12026-03-31-133.1%
Q22026-06-30-22.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$166.46K

-98.5%

Gross Profit

$129.05K

-98.5%

Gross Margin

77.53%

N/A

Market Cap

$116.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.26M

N/A

Employees

93

N/A

Net Income

-$4.12M

-455.6%

EBITDA

-$3.12M

-546.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.86M

-76.0%

Total Debt

$4.71M

-54.4%

Accounts Receivable

$13.42M

+30.1%

Inventory

$29.94K

-99.1%

Long Term Debt

$4.21M

-57.7%

Short Term Debt

$503.02K

+30.3%

Return on Assets

-16.87%

N/A

Return on Invested Capital

-34.77%

N/A

Free Cash Flow

$521.57K

-36.2%

Operating Cash Flow

$559.85K

-33.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LVTXLAVA Therapeutics N.V.
$1.74-3.87%
LTRNLantern Pharma Inc.
$2.86+2.88%
DYAIDyadic International, Inc.
$1.00-1.96%
RMTIRockwell Medical, Inc.
$7.14-0.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About CPIX

What is the current price of Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals is trading at $7.80 per share.

What is the 52-week range for Cumberland Pharmaceuticals?

Over the past 52 weeks, Cumberland Pharmaceuticals has traded between $1.43 and $8.23.

How much debt does Cumberland Pharmaceuticals have?

As of the most recent reporting period, Cumberland Pharmaceuticals reported total debt of $4.71M.

How much cash does Cumberland Pharmaceuticals have on hand?

Cumberland Pharmaceuticals reported $3.86M in cash and cash equivalents in its most recent financial results.

What is Cumberland Pharmaceuticals’s dividend yield?

Cumberland Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services